Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib PK Food Effect and Formulation Study
NCT04702698Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peposertib in solid tumor (8 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Sampling, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Jan 2021; status: completed.
02
Drugs
peposertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04702698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702698.